CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

Inclusion Criteria

• •Diagnosis of Ewing's sarcoma or Ewing's sarcoma-like tumor by institutional pathologist. The original pathological report is required. Repeat biopsy at progression is not required
• •Refractory disease or confirmed radiological progression or recurrence following first or later line of treatment of Ewing's sarcoma or Ewing's sarcoma-like tumor
• •\-- Must have one measurable or evaluable lesion per RECIST 1.1
• •Adequate performance status based on age
• •* For participants less than (\<)16 years of age, a Lansky score greater than or equal to (≥)50, or
• •* For participants ≥16 years of age, a Karnofsky score ≥50
• •Participants must have discontinued all previous treatments for cancer or investigational agents ≥7 days after the last dose and must have recovered from the acute effects
• •Adequate hematologic and organ function less than or equal to (≤)14 days prior to Day 1 of Cycle 1:
• •* Absolute neutrophil count ≥1000/microliter (µL)
• •* Platelets ≥75,000/cubic millimeter (mm³)
• •* Hemoglobin ≥8 grams per deciLiter (g/Dl) (≥100 grams per Liter \[g/L\])
• •* Total bilirubin ≤1.5 times (×) upper limit of normal (ULN)
• •* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × ULN
• •* Creatinine clearance or calculated glomerular filtration rate (GFR) ≥60 milliliters per minute per square meter (Ml/min/m²) or serum creatinine based on age/gender
• •Female participants of childbearing potential must have a negative urine or serum pregnancy test
• •Body weight ≥10 kilograms (kg)
• •Must be able to swallow and/or have a gastric/nasogastric tube
• •\-- Participants in the European Union must be able to swallow intact capsules
• •Stable or decreasing dose of steroids at least 7 days prior to enrollment
• •Life expectancy of at least 8 weeks and able to complete at least 1 cycle of treatment
• •Participants/caregivers are able and willing to make themselves available for the duration of the study and are willing to follow study procedures, including adherence to the pharmacokinetic (PK) sampling schedule